At a certain point, you think you’ve seen all of those maddening, intentionally misleading Facebook math riddles. The first one I recall led to an unfriending on Facebook — and my first article for Slate. It discussed the history of “order of operations” and the ambiguities of math “language” (and amusingly led to just as much debate in the comments as on Facebook). Continue reading
In the early days of the coronavirus pandemic, most data came from news reports, clinical summaries and preprints. Now more and more peer-reviewed studies are coming out each day, and it’s challenging to keep up with them. Several journals have set up dedicated coronavirus sites that can help in keeping up with the research.
The Lancet’s COVID-19 Resource Centre, JAMA Network’s COVID-19 resource center and NEJM’s Coronavirus (COVID-19) page all include the newest studies, commentary and related data and information on the pandemic. Continue reading
The United States Preventive Services Task Force (USPSTF) has made changes to the way they present their recommendations in hopes of making them more user-friendly for physicians. The result also is clearer and easier to follow for journalists and consumers too.
The changes, outlined in the September issue of JAMA, include better use plain language, making the recommendations more easily scannable and emphasizing top-line recommendations without repetitive or marginally relevant information. You still can get the nitty-gritty details of a recommendation and supporting evidence from the site, but for those needing a quick summary, it’s now easier to find what you need. Continue reading
How much does the way you cover a study matter? If we judge that question on the basis of how your coverage might influence a reader’s opinion about a treatment’s benefit, it matters quite a bit, suggest the results of a recent study in BMC Medicine that examined spin in news stories about clinical studies.
In short, news articles that included spin in their coverage of a study about a particular treatment were more likely to leave readers with a positive impression of the treatment’s benefit.
There’s no doubt that a diagnosis of Alzheimer’s disease is devastating for both the person who receives it and for their family.
Although it’s the sixth leading cause of death in the U.S., affecting nearly 6 million people, finding a cure or even a long-term treatment has proven elusive. Most drugs never make it out of Phase I or II trials. Continue reading
The first AHCJ conference I ever attended was in 2011 in Philadelphia. I had only recently learned about the organization and knew very little about it. I’d signed up for a field trip, but I had brought my 8-month-old with me and was up late the night before, so overslept and missed it.
When I actually got to the conference (my aunt watched my son), I caught the second half of a Thursday workshop with Ivan Oransky, M.D., (now AHCJ’s president) and Gary Schwitzer of HealthNewsReview.org on how to understand and responsibly report on medical studies. It was the session I would eventually end up leading myself years later. Continue reading